Further Studies with the 2-Amino-1,3-thiazol-4(5H)-one Class of 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors: Reducing Pregnane X Receptor Activity and Exploring Activity in a Monkey Pharmacodynamic Model
摘要:
A series of compounds containing the 2-amino-1,3-thiazol-4(5H)-one core were found to be potent inhibitors of the enzyme 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1). One of our lead compounds from this series activated the human nuclear xenobiotic receptor, pregnane X receptor (PXR). To try and mitigate the PXR activity, we prepared analogues of our lead series that contained polar groups on the right-hand side of the thiazolone. Several analogues containing amides or alcohols appended to the C-5 position of the thiazolone showed a significant reduction in PXR activity. Through these structure-activity efforts, a compound containing a tert-alcohol group off the C-5 position, analogue (S)-33a, Was found to have an 11 beta-HSD1 K(i) = 35 nM and negligible PXR activity. Compound (S)-33a was advanced into a pharmacodynamic model in cynomolgus monkeys, where it inhibited adipose 11 beta-HSD1 activity after being orally administered.
Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
申请人:Henriksson Martin
公开号:US20070197598A1
公开(公告)日:2007-08-23
The present invention relates to thiazolinones and also to pharmaceutical compositions comprising the compounds, as well as methods of use of the compounds for treatment of disorders associated with human 11-β-hydroxysteroid dehydrogenase type 1 enzyme and for the preparation of a medicament which acts on the human 11-β-hydroxysteroid dehydrogenase type 1 enzyme.
[EN] INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1<br/>[FR] INHIBITEURS DE LA 11-BETA-HYDROXY STEROIDE DESHYDROGENASE DE TYPE 1
申请人:AMGEN INC
公开号:WO2007061661A2
公开(公告)日:2007-05-31
(EN) The present invention relates to thiazolinones and also to pharmaceutical compositions comprising the compounds, as well as methods of use of the compounds for treatment of disorders associated with human 11-&bgr;-hydroxysteroid dehydrogenase type 1 enzyme and for the preparation of a medicament which acts on the human 11- &bgr;-hydroxysteroid dehydrogenase type 1 enzyme.(FR) La présente invention concerne des thiazolinones et des compositions pharmaceutiques comprenant ces composés, ainsi que des procédés d’utilisation de ces composés pour le traitement des pathologies associées à l’enzyme humaine 11-&bgr;-hydroxystéroide déshydrogénase de type 1 et pour la préparation d’un médicament agissant sur cette enzyme.
Further Studies with the 2-Amino-1,3-thiazol-4(5<i>H</i>)-one Class of 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors: Reducing Pregnane X Receptor Activity and Exploring Activity in a Monkey Pharmacodynamic Model
作者:Christopher Fotsch、Michael D. Bartberger、Eric A. Bercot、Michelle Chen、Rod Cupples、Maury Emery、Jenne Fretland、Anil Guram、Clarence Hale、Nianhe Han、Dean Hickman、Randall W. Hungate、Michael Hayashi、Renee Komorowski、Qingyian Liu、Guy Matsumoto、David J. St. Jean、Stefania Ursu、Murielle Véniant、Guifen Xu、Qiuping Ye、Chester Yuan、Jiandong Zhang、Xiping Zhang、Hua Tu、Minghan Wang
DOI:10.1021/jm801073z
日期:2008.12.25
A series of compounds containing the 2-amino-1,3-thiazol-4(5H)-one core were found to be potent inhibitors of the enzyme 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1). One of our lead compounds from this series activated the human nuclear xenobiotic receptor, pregnane X receptor (PXR). To try and mitigate the PXR activity, we prepared analogues of our lead series that contained polar groups on the right-hand side of the thiazolone. Several analogues containing amides or alcohols appended to the C-5 position of the thiazolone showed a significant reduction in PXR activity. Through these structure-activity efforts, a compound containing a tert-alcohol group off the C-5 position, analogue (S)-33a, Was found to have an 11 beta-HSD1 K(i) = 35 nM and negligible PXR activity. Compound (S)-33a was advanced into a pharmacodynamic model in cynomolgus monkeys, where it inhibited adipose 11 beta-HSD1 activity after being orally administered.